|
⚲
|
| Keyboard |
| David Grayzel | |
|---|---|
| Firm | |
| Address | 1050 Waltham Street Suite 301 Lexington, MA 02421 |
| Source |
| Associated Funds | Form D | Role | 2011 - 2026 | Raised | AUM |
|---|---|---|---|---|---|
| Triana Biomedicines Inc | 021-565748 | Director | 120.1 M of 120.1 M |
||
| Affinia Therapeutics Inc | 021-560739 | Director | 13.3 M of 45.0 M |
||
| Comanche Biopharma Corp | 021-502717 | Director | 37.5 M of 75.0 M |
||
| Triana Biomedicines Inc | 021-433414 | Director | 42.6 M of 85.1 M |
||
| Santi Therapeutics Inc | 021-413815 | Director | 10.0 M of 10.0 M |
||
| Affinia Therapeutics Inc | 021-398517 | Director | 110.0 M of 110.0 M |
||
| Xilio Therapeutics Inc | 021-390683 | Director | 95.0 M of 95.0 M |
||
| Xilio Therapeutics Inc | 021-387002 | Director | 50.2 M of 50.2 M |
||
| Aerovate Therapeutics Inc | 021-373292 | Director | 75.8 M of 75.8 M |
||
| Affinia Therapeutics Inc | 021-363863 | Director | 38.5 M of 68.5 M |
||
| Akriveia Therapeutics LLC | 021-304462 | Director | 3.0 M of 22.5 M |
||
| Annovation Biopharma Inc | 021-181765 | Executive Officer | 8.0 M of 11.0 M |
||
| Arteaus Therapeutics LLC | 021-163669 | Executive Officer | 15.6 M of 18.0 M |
||
| Annovation Biopharma Inc | 021-159952 | Executive Officer | 0.4 M of 0.8 M |
||
| Atlas Venture Life Science Advisors LLC | |||||
| Atlas Venture Fund XIV LP | 021-531177 | Executive Officer | 450.0 M of 450.0 M |
452.0 M | |
| Atlas Venture Fund XIII LP | 021-435762 | Executive Officer | 450.0 M of 450.0 M |
551.4 M | |
| Atlas Venture Opportunity Fund II LP | 021-415392 | Executive Officer | 300.0 M of 300.0 M |
287.4 M | |
| Atlas Venture Fund XII LP | 021-368325 | Executive Officer | 400.0 M of 400.0 M |
318.2 M | |
| Atlas Venture Opportunity Fund I LP | 021-326809 | Executive Officer | 250.0 M of 250.0 M |
164.0 M | |
| Atlas Venture Fund Xi LP | 021-289898 | Executive Officer | 350.0 M of 350.0 M |
340.2 M | |
| Atlas Venture Fund X LP | 021-230375 | Executive Officer | of 250.0 M |
490.8 M | |